Abstract 1792
Background
Prostate cancer (PC) is the second most common type of cancer among men. During radiotherapy (RT), some of the healthy tissues can be irradiated and side effects such as urinary (UI) and fecal incontinence (FI) may occur.
Methods
This non-randomized study was conducted to determine the effect of Kegel exercises on prevention of UI and FI in PC patients undergoing RT at the Gazi Hospital in the dates of 10.12.2016-03.01.2018. 60 patients were included in the study, 30 in the experimental and 30 in the control group. Data was collected with information form, CTCAE, EORTC QLQ-C30, REALM, weekly exercise follow-up schedule. The experimental group was provided individual training on Kegel exercises, training booklet was given, and patients were followed up weekly. Data collection forms were repeated before training, at the end of the first month and second month. No similar intervention was provided for the control group. Chi-square, Mann-Whitney U, Kruskal-Wallis, Friedman, Wilcoxon tests, variance analysis were used for the data analysis.
Results
Experimental and control groups were found to have been distributed homogeneously. At the end of first month, 10% of the experimental group and 13.3% of the control group had first grade UI. At the end of second month, only 1% of the control group had first grade UI, 3.3% of the experimental group and 6,7% of the control group had second grade UI. Besides, FI was not developed in both groups. It was found that social function of the EORTC QLQ-C30 increased in the experimental group. Additionally, diarrhea, insomnia, loss of appetite in the symptom sub-scale decreased in the same group. Improvement was observed in the overall health condition of the experimental group, whereas the control group was observed to be worse (p < 0,05).
Conclusions
Although Kegel exercises were not found effective, UI rate was lower in the experimental group. It has been recommended that Kegel exercises should be performed in larger groups with long-term observations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydan Eda Urvaylıoğlu, Sevinç Kutlutürkan, Diclehan Kılıç.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract